This section of the FEDERAL REGISTER

contains notices to the public of the proposed

issuance of rules and regulations. The

purpose of these notices is to give interested

persons an opportunity to participate in the

rule making prior to the adoption of the final

rules.

Proposed Rules Federal Register

33925 

Vol. 74, No. 133 

Tuesday, July 14, 2009 

NUCLEAR REGULATORY 

COMMISSION 

10 CFR Part 35 

[NRC–2009–0098] 

RIN 3150–AI59 

Medical Use of Byproduct Material— 

Authorized User Clarification 

AGENCY: Nuclear Regulatory 

Commission. 

ACTION: Proposed rule. 

SUMMARY: The U.S. Nuclear Regulatory 

Commission (NRC) is proposing to 

amend its regulations to clarify that 

individuals who do not need to comply 

with the training and experience 

requirements as described in the 

applicable regulations for the medical 

use of byproduct material ( i.e., are 

‘‘grandfathered’’) may serve as 

preceptors and work experience 

supervisors for individuals seeking 

recognition on NRC licenses for the 

same medical uses of byproduct 

material. The regulations that govern the 

medical use of byproduct material were 

amended in their entirety in 2002 and 

again in 2005. Currently, individuals 

who were identified on an NRC or 

Agreement State license or permit 

before the regulations were amended do 

not need to requalify by meeting the 

training and experience requirements of 

the applicable regulations. When the 

regulations were revised, the NRC 

intended that those authorized 

individuals would also be able to serve 

as preceptors and work experience 

supervisors. However, the regulations as 

they are currently written do not 

specifically state that grandfathered 

individuals can be work experience 

supervisors and preceptors. 

This proposed rule would amend the 

regulations to clarify that all individuals 

grandfathered under the applicable 

regulations may serve as preceptors and 

work experience supervisors for 

individuals seeking recognition on an 

NRC license for the same uses. 

Additionally, several minor 

administrative changes are included in 

this proposed rulemaking. 

DATES: Comments on the proposed rule 

must be received on or before August 

13, 2009. 

ADDRESSES: Please include the number 

RIN 3150–AI59 in the subject line of 

your comments. Comments on 

rulemakings submitted in writing or in 

electronic form will be made available 

to the public in their entirety on the 

NRC’s Web site in the Agencywide 

Documents Access and Management 

System (ADAMS) and at http:// 

www.regulations.gov. Personal 

information, such as your name, 

address, telephone number, e-mail 

address, etc., will not be removed from 

your submission. You may submit 

comments by any one of the following 

methods: 

Federal e-Rulemaking portal: Go to 

http://www.regulations.gov and search 

for documents filed under Docket ID 

NRC–2009–0098 and follow instructions 

for submitting comments. Address 

questions about NRC dockets to Carol 

Gallagher 301–492–3668; e-mail 

Carol.Gallagher@nrc.gov. 

Mail comments to: Secretary, U.S. 

Nuclear Regulatory Commission, 

Washington, DC 20555–0001, ATTN: 

Rulemakings and Adjudications Staff. 

E-mail comments to: 

Rulemaking.Comments@nrc.gov. If you 

do not receive a reply e-mail confirming 

that we have received your comments, 

contact us directly at 301–415–1677. 

Hand-deliver comments to: 11555 

Rockville Pike, Rockville, Maryland 

20852, between 7:30 a.m. and 4:15 p.m. 

Federal workdays. (Telephone 301–415– 

1677). 

Fax comments to: Secretary, U.S. 

Nuclear Regulatory Commission at 301– 

415–1101. 

Publicly available documents related 

to this rulemaking may be viewed 

electronically on the public computers 

located at the NRC’s Public Document 

Room (PDR), Room O–1 F21, One White 

Flint North, 11555 Rockville Pike, 

Rockville, Maryland. The PDR 

reproduction contractor will copy 

documents for a fee. Selected 

documents, including any comments, 

may be viewed and downloaded via the 

e-Rulemaking Portal at http:// 

www.regulations.gov. 

Publicly available documents created 

or received at the NRC after November 

1, 1999, are available electronically at 

the NRC’s Electronic Reading Room at 

http://www.nrc.gov/reading-rm/ 

adams.html. From this site, the public 

can gain entry into ADAMS, which 

provides text and image files of NRC’s 

public documents. If you do not have 

access to ADAMS or if there are 

problems in accessing the documents 

located in ADAMS, contact the PDR 

Reference staff at 1–800–397–4209, 301– 

415–4737 or by e-mail to 

pdr.resource@nrc.gov. 

FOR FURTHER INFORMATION CONTACT: 

Edward M. Lohr, Office of Federal and 

State Materials and Environmental 

Management Programs, U.S. Nuclear 

Regulatory Commission, Washington, 

DC 20555–0001, telephone 301–415– 

0253, e-mail, Edward.Lohr@nrc.gov. 

SUPPLEMENTARY INFORMATION: For 

additional information see the Direct 

Final Rule published in the final rules 

section of this Federal Register. 

Procedural Background 

Because NRC considers this action 

noncontroversial and routine, we are 

publishing this proposed rule 

concurrently as a direct final rule. The 

direct final rule will become effective on 

September 28, 2009. However, if the 

NRC receives a significant adverse 

comment on the proposed rule by 

August 13, 2009, then the NRC will 

publish a document to withdraw the 

direct final rule. If the direct final rule 

is withdrawn, the NRC will address the 

comments received in response to the 

proposed revisions in a subsequent final 

rule. Absent significant modifications to 

the proposed revisions requiring 

republication, the NRC will not initiate 

a second comment period for this action 

if the direct final rule is withdrawn. 

A significant adverse comment is a 

comment where the commenter 

explains why the rule would be 

inappropriate, including challenges to 

the rule’s underlying premise or 

approach, or would be ineffective or 

unacceptable without a change. A 

comment is adverse and significant if: 

(1) The comment opposes the rule and 

provides a reason sufficient to require a 

substantive response in a notice-andcomment process. For example, a 

substantive response is required when: 

(a) The comment causes the NRC staff 

to reevaluate (or reconsider) its position 

or conduct additional analysis; 

(b) The comment raises an issue 

serious enough to warrant a substantive 


sroberts on DSKD5P82C1PROD with PROPOSALS
33926 Federal Register / Vol. 74, No. 133 / Tuesday, July 14, 2009 / Proposed Rules 

response to clarify or complete the 

record; or 

(c) The comment raises a relevant 

issue that was not previously addressed 

or considered by the NRC staff. 

(2) The comment proposes a change 

or an addition to the rule, and it is 

apparent that the rule would be 

ineffective or unacceptable without 

incorporation of the change or addition. 

(3) The comment causes the staff to 

make a change (other than editorial) to 

the rule. 

List of Subjects in 10 CFR Part 35 

Byproduct material, Criminal 

penalties, Drugs, Health facilities, 

Health professions, Medical devices, 

Nuclear materials, Occupational safety 

and health, Radiation protection, 

Reporting and recordkeeping 

requirements. 

For the reasons set out in the 

preamble and under the authority of the 

Atomic Energy Act of 1954, as amended; 

the Energy Reorganization Act of 1974, 

as amended; and 5 U.S.C. 553; the NRC 

is proposing to adopt the following 

amendments to 10 CFR part 35. 

PART 35—MEDICAL USE OF 

BYPRODUCT MATERIAL 

1. The authority citation for part 35 

continues to read as follows: 

Authority: Secs. 81, 161, 182, 183, 68 Stat. 

935, 948, 953, 954, as amended (42 U.S.C. 

2111, 2201, 2232, 2233); sec. 201, 88 Stat. 

1242, as amended (42 U.S.C. 5841); sec. 1704, 

112 Stat. 2750 (44 U.S.C. 3504 note); sec. 

651(e), Pub. L. 109–58, 119 Stat. 806–810 (42 

U.S.C. 2014, 2021, 2021b, 2111). 

2. In § 35.50, paragraph (a)(2)(ii)(B) is 

revised to read as follows: 

§ 35.50 Training for Radiation Safety 

Officer. 

* * * * * 

(a) * * * 

(2) * * * 

(ii) * * * 

(B) In clinical nuclear medicine 

facilities providing diagnostic and/or 

therapeutic services under the direction 

of physicians who meet the 

requirements for authorized users in 

§§ 35.57, 35.290, or 35.390; 

* * * * * 

3. In § 35.51, paragraphs (a)(2)(ii) and 

(b)(2) are revised to read as follows: 

§ 35.51 Training for an authorized medical 

physicist. 

* * * * * 

(a) * * * 

(2) * * * 

(ii) In clinical radiation facilities 

providing high-energy, external beam 

therapy (photons and electrons with 

energies greater than or equal to 1 

million electron volts) and 

brachytherapy services under the 

direction of physicians who meet the 

requirements in §§ 35.57, 35.490, or 

35.690; and 

* * * * * 

(b) * * * 

(2) Has obtained written attestation 

that the individual has satisfactorily 

completed the requirements in 

paragraphs (c) and (a)(1) and (a)(2), or 

(b)(1) and (c) of this section, and has 

achieved a level of competency 

sufficient to function independently as 

an authorized medical physicist for each 

type of therapeutic medical unit for 

which the individual is requesting 

authorized medical physicist status. The 

written attestation must be signed by a 

preceptor authorized medical physicist 

who meets the requirements in §§ 35.51, 

35.57, or equivalent Agreement State 

requirements for an authorized medical 

physicist for each type of therapeutic 

medical unit for which the individual is 

requesting authorized medical physicist 

status; and 

* * * * * 

4. In § 35.57, a new paragraph (c) is 

added to read as follows: 

§ 35.57 Training for experienced Radiation 

Safety Officer, teletherapy or medical 

physicist, authorized medical physicist, 

authorized user, nuclear pharmacist, and 

authorized nuclear pharmacist. 

* * * * * 

(c) Individuals who need not comply 

with training requirements as described 

in this section may serve as preceptors 

for, and supervisors of, applicants 

seeking authorization on NRC licenses 

for the same uses for which these 

individuals are authorized. 

5. In § 35.190, the introductory text of 

paragraph (c)(1)(ii) and paragraph (c)(2) 

are revised to read as follows: 

§ 35.190 Training for uptake, dilution, and 

excretion studies. 

* * * * * 

(c)(1) * * * 

(ii) Work experience, under the 

supervision of an authorized user who 

meets the requirements in §§ 35.57, 

35.190, 35.290, 35.390, or equivalent 

Agreement State requirements, 

involving— 

* * * * * 

(2) Has obtained written attestation, 

signed by a preceptor authorized user 

who meets the requirements in §§ 35.57, 

35.190, 35.290, or 35.390, or equivalent 

Agreement State requirements, that the 

individual has satisfactorily completed 

the requirements in paragraph (a)(1) or 

(c)(1) of this section and has achieved a 

level of competency sufficient to 

function independently as an 

authorized user for the medical uses 

authorized under § 35.100. 

6. In § 35.290, the introductory text of 

paragraph (c)(1)(ii) and paragraph (c)(2) 

are revised to read as follows: 

§ 35.290 Training for imaging and 

localization studies. 

* * * * * 

(c)(1) * * * 

(ii) Work experience, under the 

supervision of an authorized user who 

meets the requirements in §§ 35.57, 

35.290, or 35.390 and 35.290(c)(1)(ii)(G), 

or equivalent Agreement State 

requirements, involving— 

* * * * * 

(2) Has obtained written attestation, 

signed by a preceptor authorized user 

who meets the requirements in §§ 35.57, 

35.290, or 35.390 and 35.290(c)(1)(ii)(G), 

or equivalent Agreement State 

requirements, that the individual has 

satisfactorily completed the 

requirements in paragraph (a)(1) or 

(c)(1) of this section and has achieved a 

level of competency sufficient to 

function independently as an 

authorized user for the medical uses 

authorized under §§ 35.100 and 35.200. 

7. In § 35.390, the introductory text of 

paragraph (b)(1)(ii) and paragraph (b)(2) 

are revised to read as follows: 

§ 35.390 Training for use of unsealed 

byproduct material for which a written 

directive is required. 

* * * * * 

(b)(1) * * * 

(ii) Work experience, under the 

supervision of an authorized user who 

meets the requirements in §§ 35.57, 

35.390, or equivalent Agreement State 

requirements. A supervising authorized 

user, who meets the requirements in 

§ 35.390(b), must also have experience 

in administering dosages in the same 

dosage category or categories (i.e., 

§ 35.390(b)(1)(ii)(G)) as the individual 

requesting authorized user status. The 

work experience must involve— 

* * * * * 

(2) Has obtained written attestation 

that the individual has satisfactorily 

completed the requirements in 

paragraphs (a)(1) and (b)(1)(ii)(G) or 

(b)(1) of this section, and has achieved 

a level of competency sufficient to 

function independently as an 

authorized user for the medical uses 

authorized under § 35.300. The written 

attestation must be signed by a 

preceptor authorized user who meets 

the requirements in §§ 35.57, 35.390, or 

equivalent Agreement State 

requirements. The preceptor authorized 

user, who meets the requirements in 

§ 35.390(b) must have experience in 


sroberts on DSKD5P82C1PROD with PROPOSALS
Federal Register / Vol. 74, No. 133 / Tuesday, July 14, 2009 / Proposed Rules 33927 

administering dosages in the same 

dosage category or categories (i.e., 

§ 35.390(b)(1)(ii)(G)) as the individual 

requesting authorized user status. 

8. In § 35.392, the introductory text of 

paragraph (c)(2) and paragraph (c)(3) are 

revised to read as follows: 

§ 35.392 Training for the oral 

administration of sodium iodide I–131 

requiring a written directive in quantities 

less than or equal to 1.22 gigabecquerels 

(33 millicuries). 

* * * * * 

(c) * * * 

(2) Has work experience, under the 

supervision of an authorized user who 

meets the requirements in §§ 35.57, 

35.390, 35.392, 35.394, or equivalent 

Agreement State requirements. A 

supervising authorized user who meets 

the requirements in § 35.390(b) must 

also have experience in administering 

dosages as specified in 

§§ 35.390(b)(1)(ii)(G)(1) or 

35.390(b)(1)(ii)(G)(2). The work 

experience must involve— 

* * * * * 

(3) Has obtained written attestation 

that the individual has satisfactorily 

completed the requirements in 

paragraphs (c)(1) and (c)(2) of this 

section, and has achieved a level of 

competency sufficient to function 

independently as an authorized user for 

medical uses authorized under § 35.300. 

The written attestation must be signed 

by a preceptor authorized user who 

meets the requirements in §§ 35.57, 

35.390, 35.392, 35.394, or equivalent 

Agreement State requirements. A 

preceptor authorized user, who meets 

the requirement in § 35.390(b), must 

also have experience in administering 

dosages as specified in 

§§ 35.390(b)(1)(ii)(G)(1) or 

35.390(b)(1)(ii)(G)(2). 

9. In § 35.394, the introductory text of 

paragraph (c)(2) and paragraph (c)(3) are 

revised to read as follows: 

§ 35.394 Training for the oral 

administration of sodium iodide I–131 

requiring a written directive in quantities 

greater than 1.22 gigabecquerels (33 

millicuries). 

* * * * * 

(c) * * * 

(2) Has work experience, under the 

supervision of an authorized user who 

meets the requirements in §§ 35.57, 

35.390, 35.394, or equivalent Agreement 

State requirements. A supervising 

authorized user, who meets the 

requirements in § 35.390(b), must also 

have experience in administering 

dosages as specified in 

§ 35.390(b)(1)(ii)(G)(2). The work 

experience must involve— 

* * * * * 

(3) Has obtained written attestation 

that the individual has satisfactorily 

completed the requirements in 

paragraphs (c)(1) and (c)(2) of this 

section, and has achieved a level of 

competency sufficient to function 

independently as an authorized user for 

medical uses authorized under § 35.300. 

The written attestation must be signed 

by a preceptor authorized user who 

meets the requirements in §§ 35.57, 

35.390, 35.394, or equivalent Agreement 

State requirements. A preceptor 

authorized user, who meets the 

requirements in § 35.390(b), must also 

have experience in administering 

dosages as specified in 

§ 35.390(b)(1)(ii)(G)(2). 

10. In § 35.396, the introductory text 

of paragraph (d)(2) and paragraph (d)(3) 

are revised to read as follows: 

§ 35.396 Training for the parenteral 

administration of unsealed byproduct 

material requiring a written directive. 

* * * * * 

(d) * * * 

(2) Has work experience, under the 

supervision of an authorized user who 

meets the requirements in §§ 35.57, 

35.390, 35.396, or equivalent Agreement 

State requirements, in the parenteral 

administration, for which a written 

directive is required, of any beta emitter, 

or any photon-emitting radionuclide 

with a photon energy less than 150 keV, 

and/or parenteral administration of any 

other radionuclide for which a written 

directive is required. A supervising 

authorized user who meets the 

requirements in § 35.390 must have 

experience in administering dosages as 

specified in §§ 35.390(b)(1)(ii)(G)(3) 

and/or 35.390(b)(1)(ii)(G)(4). The work 

experience must involve— 

* * * * * 

(3) Has obtained written attestation 

that the individual has satisfactorily 

completed the requirements in 

paragraph (b) or (c) of this section, and 

has achieved a level of competency 

sufficient to function independently as 

an authorized user for the parenteral 

administration of unsealed byproduct 

material requiring a written directive. 

The written attestation must be signed 

by a preceptor authorized user who 

meets the requirements in §§ 35.57, 

35.390, 35.396, or equivalent Agreement 

State requirements. A preceptor 

authorized user, who meets the 

requirements in § 35.390, must have 

experience in administering dosages as 

specified in §§ 35.390(b)(1)(ii)(G)(3) 

and/or 35.390(b)(1)(ii)(G)(4). 

11. In § 35.490, the introductory text 

of paragraph (b)(1)(ii) and paragraphs 

(b)(2) and (b)(3) are revised to read as 

follows: 

§ 35.490 Training for use of manual 

brachytherapy sources. 

* * * * * 

(b)(1) * * * 

(ii) 500 hours of work experience, 

under the supervision of an authorized 

user who meets the requirements in 

§§ 35.57, 35.490, or equivalent 

Agreement State requirements at a 

medical institution, involving— 

* * * * * 

(2) Has completed 3 years of 

supervised clinical experience in 

radiation oncology, under an authorized 

user who meets the requirements in 

§§ 35.57, 35.490, or equivalent 

Agreement State requirements, as part of 

a formal training program approved by 

the Residency Review Committee for 

Radiation Oncology of the Accreditation 

Council for Graduate Medical Education 

or the Royal College of Physicians and 

Surgeons of Canada or the Committee 

on Postdoctoral Training of the 

American Osteopathic Association. This 

experience may be obtained 

concurrently with the supervised work 

experience required by paragraph 

(b)(1)(ii) of this section; and 

(3) Has obtained written attestation, 

signed by a preceptor authorized user 

who meets the requirements in §§ 35.57, 

35.490, or equivalent Agreement State 

requirements, that the individual has 

satisfactorily completed the 

requirements in paragraph (a)(1), or 

paragraphs (b)(1) and (b)(2), of this 

section and has achieved a level of 

competency sufficient to function 

independently as an authorized user of 

manual brachytherapy sources for the 

medical uses authorized under § 35.400. 

12. In § 35.491, paragraph (b)(3) is 

revised to read as follows: 

§ 35.491 Training for ophthalmic use of 

strontium-90. 

* * * * * 

(b) * * * 

(3) Has obtained written attestation, 

signed by a preceptor authorized user 

who meets the requirements in §§ 35.57, 

35.490, 35.491, or equivalent Agreement 

State requirements, that the individual 

has satisfactorily completed the 

requirements in paragraph (b) of this 

section and has achieved a level of 

competency sufficient to function 

independently as an authorized user of 

strontium-90 for ophthalmic use. 

13. In § 35.690, the introductory text 

of paragraph (b)(1)(ii) and paragraphs 

(b)(2) and (b)(3) are revised to read as 

follows: 

§ 35.690 Training for use of remote 

afterloader units, teletherapy units, and 

gamma stereotactic radiosurgery units. 

* * * * * 


sroberts on DSKD5P82C1PROD with PROPOSALS
33928 Federal Register / Vol. 74, No. 133 / Tuesday, July 14, 2009 / Proposed Rules 

(b)(1) * * * 

(ii) 500 hours of work experience, 

under the supervision of an authorized 

user who meets the requirements in 

§§ 35.57, 35.690, or equivalent 

Agreement State requirements at a 

medical institution, involving— 

* * * * * 

(2) Has completed 3 years of 

supervised clinical experience in 

radiation therapy, under an authorized 

user who meets the requirements in 

§§ 35.57, 35.690, or equivalent 

Agreement State requirements, as part of 

a formal training program approved by 

the Residency Review Committee for 

Radiation Oncology of the Accreditation 

Council for Graduate Medical Education 

or the Royal College of Physicians and 

Surgeons of Canada or the Committee 

on Postdoctoral Training of the 

American Osteopathic Association. This 

experience may be obtained 

concurrently with the supervised work 

experience required by paragraph 

(b)(1)(ii) of this section; and 

(3) Has obtained written attestation 

that the individual has satisfactorily 

completed the requirements in 

paragraph (a)(1) or paragraphs (b)(1) and 

(b)(2), and paragraph (c), of this section, 

and has achieved a level of competency 

sufficient to function independently as 

an authorized user of each type of 

therapeutic medical unit for which the 

individual is requesting authorized user 

status. The written attestation must be 

signed by a preceptor authorized user 

who meets the requirements in §§ 35.57, 

35.690, or equivalent Agreement State 

requirements for an authorized user for 

each type of therapeutic medical unit 

for which the individual is requesting 

authorized user status; and 

* * * * * 

Dated at Rockville, Maryland, this 26th day 

of June 2009. 

For the Nuclear Regulatory Commission. 

R.W. Borchardt, 

Executive Director for Operations. 

[FR Doc. E9–16656 Filed 7–13–09; 8:45 am] 

BILLING CODE 7590–01–P 

DEPARTMENT OF TRANSPORTATION 

Federal Aviation Administration 

14 CFR Part 39 

[Docket No. FAA–2009–0636; Directorate 

Identifier 2009–NM–031–AD] 

RIN 2120–AA64 

Airworthiness Directives; Boeing 

Model 747–100B SUD, –200B, –300, 

–400, and –400D Series Airplanes 

AGENCY: Federal Aviation 

Administration (FAA), Department of 

Transportation (DOT). 

ACTION: Notice of proposed rulemaking 

(NPRM). 

SUMMARY: The FAA proposes to 

supersede an existing airworthiness 

directive (AD) that applies to certain 

Boeing Model 747–100B SUD, –200B, 

–300, –400, and –400D series airplanes. 

The existing AD currently requires 

repetitive inspections for cracking in 

fuselage stringers 8L, 8R, 10L, and 10R 

at body stations 460, 480, and 500 frame 

locations; and repair if necessary. This 

proposed AD would revise the 

applicability to include an additional 

airplane, and reduce compliance times 

for the initial inspection and repetitive 

intervals for Model 747–400 series 

airplanes that have been converted to 

the large cargo freighter configuration. 

This proposed AD results from findings 

of cracking in fuselage stringers 8L, 8R, 

10L, and 10R at body stations 460, 480, 

and 500 frame locations. We are 

proposing this AD to detect and correct 

fatigue cracking in certain fuselage 

stringers, which, if left undetected, 

could result in fuselage skin cracking 

that reduces the structural integrity of 

the skin panel, and consequent rapid 

depressurization of the airplane. 

DATES: We must receive comments on 

this proposed AD by August 28, 2009. 

ADDRESSES: You may send comments by 

any of the following methods: 

• Federal eRulemaking Portal: Go to 

http://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Fax: 202–493–2251. 

• Mail: U.S. Department of 

Transportation, Docket Operations, M– 

30, West Building Ground Floor, Room 

W12–140, 1200 New Jersey Avenue, SE., 

Washington, DC 20590. 

• Hand Delivery: U.S. Department of 

Transportation, Docket Operations, M– 

30, West Building Ground Floor, Room 

W12–140, 1200 New Jersey Avenue, SE., 

Washington, DC 20590, between 9 a.m. 

and 5 p.m., Monday through Friday, 

except Federal holidays. 

For service information identified in 

this proposed AD, contact Boeing 

Commercial Airplanes, Attention: Data 

& Services Management, P.O. Box 3707, 

MC 2H–65, Seattle, Washington 98124– 

2207; telephone 206–544–5000, 

extension 1; fax 206–766–5680; e-mail 

me.boecom@boeing.com; Internet 

https://www.myboeingfleet.com. You 

may review copies of the referenced 

service information at the FAA, 

Transport Airplane Directorate, 1601 

Lind Avenue, SW., Renton, Washington. 

For information on the availability of 

this material at the FAA, call 425–227– 

1221 or 425–227–1152. 

Examining the AD Docket 

You may examine the AD docket on 

the Internet at http:// 

www.regulations.gov; or in person at the 

Docket Management Facility between 9 

a.m. and 5 p.m., Monday through 

Friday, except Federal holidays. The AD 

docket contains this proposed AD, the 

regulatory evaluation, any comments 

received, and other information. The 

street address for the Docket Office 

(telephone 800–647–5527) is in the 

ADDRESSES section. Comments will be 

available in the AD docket shortly after 

receipt. 

FOR FURTHER INFORMATION CONTACT: Ivan 

Li, Aerospace Engineer, Airframe 

Branch, ANM–120S, FAA, Seattle 

Aircraft Certification Office, 1601 Lind 

Avenue, SW., Renton, Washington 

98057–3356; telephone (425) 917–6437; 

fax (425) 917–6590. 

SUPPLEMENTARY INFORMATION: 

Comments Invited 

We invite you to send any written 

relevant data, views, or arguments about 

this proposed AD. Send your comments 

to an address listed under the 

ADDRESSES section. Include ‘‘Docket No. 

FAA–2009–0636; Directorate Identifier 

2009–NM–031–AD’’ at the beginning of 

your comments. We specifically invite 

comments on the overall regulatory, 

economic, environmental, and energy 

aspects of this proposed AD. We will 

consider all comments received by the 

closing date and may amend this 

proposed AD because of those 

comments. 

We will post all comments we 

receive, without change, to http:// 

www.regulations.gov, including any 

personal information you provide. We 

will also post a report summarizing each 

substantive verbal contact we receive 

about this proposed AD. 

Discussion 

On July 13, 2005, we issued AD 2005– 

15–08, amendment 39–14197 (70 FR 

43020, July 26, 2005), for certain Boeing 

Model 747–100B SUD, –200B, –300, 

–400, and –400D series airplanes. That 


sroberts on DSKD5P82C1PROD with PROPOSALS